3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
OTHER
4
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
14
Lymphoma, Non-Hodgkin
6
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Hodgkin Disease
2
Waldenstrom Macroglobulinemia
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Gastrointestinal Stromal Tumors
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Interventions
Rituximab
30
ibrutinib
26
Bendamustine Hydrochloride
18
Cyclophosphamide
17
acalabrutinib
14
fludarabine
13
Lenalidomide
11
zanubrutinib
10
venetoclax
9
Vincristine
7
Bortezomib
7
pirtobrutinib
5
brexucabtagene autoleucel
5
Prednisone
5
Doxorubicin
5
temsirolimus
4
parsaclisib
4
aflibercept
4
Gemcitabine
4
ublituximab
3
orelabrutinib
3
loncastuximab tesirine
3
idelalisib
3
ibritumomab tiuxetan
3
Sensitivity and Specificity
3
Antigens, CD19
3
tositumomab I-131
2
tazemetostat
2
pembrolizumab
2
fludarabine phosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Mantle-Cell
×
umbralisib
×
Clear all
NCT02793583
2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3
Terminated
710 enrolled
1 FDA